Geoffrey B. Johnson, MD, PhD, presented “Appropriate Use of PSMA PET in Clinical Practice” during the 33rd International Prostate Cancer Update on January 24, 2023, in Vail, Colorado.
How to cite: Johnson, Geoffrey B. “Appropriate Use of PSMA PET in Clinical Practice.” January 24, 2023. Accessed Dec 2024. https://grandroundsinurology.com/appropriate-use-of-psma-pet-in-clinical-practice-2/
Appropriate Use of PSMA PET in Clinical Practice – Summary
Geoffrey B. Johnson, MD, PhD, delivers an informative presentation on the appropriate utilization of PSMA PET in clinical practice, delving into various aspects of this advanced imaging technique. Dr. Johnson begins by elucidating the diverse range of prostate cancer PET radiotracers available, with a particular focus on the recently FDA-approved PSMA imaging agents.
In addition to discussing the different types of PET radiotracers, Dr. Johnson also delves into the complex landscape of reimbursement criteria for PSMA PET. Drawing comparisons to traditional imaging methods, he highlights the advantages of PSMA PET in terms of its ability to detect prostate cancer metastases more accurately, paving the way for enhanced diagnostic accuracy and improved treatment decision-making.
About The 33rd Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 33rd iteration of the meeting occurred January 22-25, 2023 in Vail, Colorado. To view more educational presentations from IPCU 33, visit our collection page.
ABOUT THE AUTHOR
Dr. Geoffrey Johnson is a thoracic radiologist and nuclear medicine physician at the Mayo Clinic in Rochester, MN and is chair of the nuclear medicine division. He received his undergraduate degree in chemical engineering at MIT, his medical degree from the Mayo Clinic School of Medicine, and his Ph.D. in Immunology from Mayo Graduate School. He specializes in nuclear cardiology, nuclear medicine, thoracic imaging, and nuclear radiology and is experienced in nuclear therapy, amyloidosis, positron emission tomography (PET/CT and PET/MR), and lung neoplasms. He has a joint appointment in immunology.
Dr. Johnson’s research interests include PET and SPECT imaging of malignancy, infectious and inflammatory diseases, cardiac and systemic amyloidosis and radionuclide therapy. He has served as principal investigator (PI) and co-principal investigator on radionuclide therapy trials and was the PI on the Mayo Clinic’s early access protocol for 68Ga-PSMA-11 PET imaging.
